الإحصائيات الأساسية
| LEI | 54930017PANCHC5LYH79 |
| CIK | 1598646 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Minerva Neurosciences, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neurosciences, |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neurosciences, |
|
| April 29, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission |
|
| April 21, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission |
|
| April 21, 2025 |
Amended and Restated Non-Employee Director Compensation Plan Exhibit 10.12 AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PLAN Approved: March 7, 2018 Effective: April 1, 2018 Last approved on December 5, 2024, effective as of January 1, 2025 (the “Effective Date”) Cash Compensation Effective as of the Effective Date, each non-employee member of the board of directors (the “Board”) of Minerva Neurosciences, Inc. (the “Company”) will receive an annu |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commiss |
|
| February 25, 2025 |
Statement of Company Policy on Insider Trading and Disclosure Exhibit 19.1 Minerva Neurosciences, Inc. Insider Trading Policy (adopted February 20, 2025) Introduction During the course of your relationship with Minerva Neurosciences, Inc. (“Minerva”), you may receive material information that is not yet publicly available (“material nonpublic information”) about Minerva or other publicly traded companies that Minerva has business relationships with. Material |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36517 Minerva Neurosc |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neuroscien |
|
| October 22, 2024 |
DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| October 22, 2024 |
DEFA14A 1 d843316ddefa14a.htm DEFA14A SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definiti |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2024 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commis |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2024 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Com |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neurosciences, |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commissio |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neurosciences, |
|
| April 22, 2024 |
Amended and Restated Non-Employee Director Compensation Plan Exhibit 10.12 AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PLAN Approved: March 7, 2018 Effective: April 1, 2018 Last approved on November 29, 2023, effective as of January 1, 2024 (the “Effective Date”) Effective as of the Effective Date, each non-employee member of the board of directors (the “Board”) of Minerva Neurosciences, Inc. (the “Company”) will receive an annual cash retainer |
|
| April 22, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commiss |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| February 27, 2024 |
Exhibit 99.1 Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia BURLINGTON, Mass., – February 27, 2024 (GLOBE NEWSWIRE) – Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No.1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File N |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36517 Minerva Neurosc |
|
| February 22, 2024 |
Incentive Compensation Recoupment Policy Exhibit 97 Minerva Neurosciences, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Minerva Neurosciences, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Po |
|
| January 18, 2024 |
US6033802058 / Minerva Neurosciences Inc / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 nerv1573-form.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10*) MINERVA NEUROSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 603380205 (CUSIP Number) December 31, 2023 (Date of |
|
| November 7, 2023 |
Amended and Restated Non-Employee Director Compensation Plan EXHIBIT 10.1 AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PLAN Approved: March 7, 2018 Effective: April 1, 2018 As amended as of July 30, 2023 (the “Effective Date”) Effective as of the Effective Date, each non-employee member of the board of directors (the “Board”) of Minerva Neurosciences, Inc. (the “Company”) will receive an annual cash retainer of $35,000, the Lead Independent Direc |
|
| November 7, 2023 |
Amended and Restated 2013 Equity Incentive Plan EXHIBIT 10.2 Minerva Neurosciences, Inc. Amended and Restated 2013 Equity Incentive Plan Adopted by Board of Directors on: December 19, 2013 Approved by the Stockholders on: December 19, 2013 Amended and Restated by the Board of Directors on: April 29, 2014 Amendment and Restatement Approved by the Stockholders on: June 2, 2014 Amended and restated by the Board of Directors on: April 21, 2018 Amen |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neuroscien |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Com |
|
| August 15, 2023 |
DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 15, 2023 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 9, 2023 |
Up to 2,000,575 Shares of Common Stock Offered by the Selling Stockholders Table of Contents As Filed Pursuant to Rule 424(b)(3) Registration No. 333-273686 PROSPECTUS Up to 2,000,575 Shares of Common Stock Offered by the Selling Stockholders This prospectus relates to the resale from time to time of up to 2,000,575 shares of common stock, par value $0.0001 per share, of Minerva Neurosciences, Inc. (the “Common Stock”) by the selling stockholders listed on page 9 (the “S |
|
| August 7, 2023 |
August 7, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jimmy McNamara Re: Minerva Neurosciences, Inc. Registration Statement on Form S-3 File No. 333-273686 Acceleration Request Requested Date: August 9, 2023 Requested Time: 4:00 PM Eastern Daylight Time Ladies and Gentlemen: In accordance with Rule 461 under |
|
| August 4, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Minerva Neurosciences, Inc. |
|
| August 4, 2023 |
As filed with the Securities and Exchange Commission on August 4, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on August 4, 2023 Registration No. |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neurosciences, |
|
| July 7, 2023 |
Joint Filing Agreement among Boehringer AG and Boehringer Ingelheim International GmbH. EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each sha |
|
| July 7, 2023 |
NERV / Minerva Neurosciences Inc / Boehringer AG - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 MINERVA NEUROSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 603380106 (CUSIP Number) Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein, Germany Attention: Head of Corp. Legal |
|
| June 28, 2023 |
EX-10.1 Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of June 27, 2023, is made by and among MINERVA NEUROSCIENCES, INC., a Delaware corporation (the “Company”), and the Purchasers listed on Exhibit A hereto, together with their permitted transferees (each, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. |
|
| June 28, 2023 |
Form of Pre-Funded Warrant (June 2023) EX-4.1 Exhibit 4.1 Execution Version FORM OF PRE-FUNDED WARRANT NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYP |
|
| June 28, 2023 |
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market Exhibit 99.1 Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market BURLINGTON, Mass., – June 28, 2023 (GLOBE NEWSWIRE) – Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it has agreed to sell an aggregate of 1,425,000 |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commissi |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commissi |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commissio |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neurosciences, |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commission |
|
| May 1, 2023 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia FDA grants appeal and files NDA BURLINGTON, Mass. – May 1, 2023 – (Globe Newswire) Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous sy |
|
| May 1, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commission |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3 |
|
| March 8, 2023 |
Exhibit 10.30 SECOND AMENDMENT TO THE EMPLOYMENT AGREEMENT OF REMY LUTHRINGER This Second Amendment to the Employment Agreement Of Remy Luthringer (the “Amendment”) is entered into this 6th day of March 2023 (the “Effective Date”), by and between Remy Luthringer (the “Employee”) and Mind-NRG SARL (the “Company”). Recitals A. The Company and the Employee have entered into that certain Employment Ag |
|
| March 8, 2023 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.2 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Minerva Neurosciences, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following description of our common stock is a summary, does not purport to b |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36517 Minerva Neurosc |
|
| February 14, 2023 |
SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A, AMENDMENT #1 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Minerva Neurosciences, Inc. (Tit |
|
| February 9, 2023 |
US6033802058 / Minerva Neurosciences Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Minerva Neurosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 603380205 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 1, 2023 |
US6033802058 / Minerva Neurosciences Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9*) MINERVA NEUROSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 603380205 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing o |
|
| December 28, 2022 |
Exhibit 99.1 Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia BURLINGTON, Mass. ? December 28, 2022 ? (Globe Newswire) Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today an |
|
| December 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| December 16, 2022 |
Exhibit 10.1 Execution Version FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF REMY LUTHRINGER This FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF REMY LUTHRINGER (the ?Amendment?) is entered into this 13th day of December 2022 (the ?Effective Date?), by and between REMY LUTHRINGER (the ?Employee?) and Mind-NRG SARL (the ?Company?). RECITALS A. The Company and the Employee have entered into that ce |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neuroscien |
|
| October 17, 2022 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia BURLINGTON, Mass. – October 17, 2022 – (Globe Newswire) Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat |
|
| October 17, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| September 21, 2022 |
September 21, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Abby Adams Re: Minerva Neurosciences, Inc. Registration Statement on Form S-3 File No. 333- 267424 Acceleration Request Requested Date: September 23, 2022 Requested Time: 4:00 PM Eastern Daylight Time Ladies and Gentlemen: In accordance with Rule 461 |
|
| September 14, 2022 |
MINERVA NEUROSCIENCES, INC. 1500 District Avenue Burlington, MA 01803 CORRESP 1 filename1.htm MINERVA NEUROSCIENCES, INC. 1500 District Avenue Burlington, MA 01803 September 14, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Julie Sherman Brian Cascio Re: Minerva Neurosciences, Inc. (the “Company”) Form 10-K for the Fiscal Year Ended December 31, 2021 |
|
| September 14, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.6 MINERVA NEUROSCIENCES, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF MINERVA NEUROSCIENCES, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between MINERVA NEUROSCIENCES, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and |
|
| September 14, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.8 MINERVA NEUROSCIENCES, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF MINERVA NEUROSCIENCES, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between MINERVA NEUROSCIENCES, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] orga |
|
| September 14, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.7 MINERVA NEUROSCIENCES, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF MINERVA NEUROSCIENCES, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between MINERVA NEUROSCIENCES, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] orga |
|
| September 14, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Minerva Neurosciences, Inc. |
|
| September 14, 2022 |
Exhibit 4.4 MINERVA NEUROSCIENCES, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 |
|
| September 14, 2022 |
Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM September 14, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Minerva Neurosciences, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s |
|
| September 14, 2022 |
Power of Attorney (included on the signature page) Table of Contents As filed with the Securities and Exchange Commission on September 14, 2022 Registration No. |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| September 9, 2022 |
Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market Exhibit 99.1 Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market BURLINGTON, Mass. ? September 9, 2022 ? (Globe Newswire) Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported a listing transfer from The Nasdaq Global Market to The Nasdaq Ca |
|
| August 23, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| August 23, 2022 |
NERV / Minerva Neurosciences Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) Minerva Neurosciences, Inc. (Title of Class of Securities) Common Stock, $0.0001 Par V |
|
| August 22, 2022 |
Exhibit 99.1 Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia WALTHAM, Mass. ? August 22, 2022 ? (Globe Newswire) Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announce |
|
| August 22, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commis |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neurosciences, |
|
| June 17, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MINERVA NEUROSCIENCES, INC. Minerva Neurosciences, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify that: FIRST: The name of the Corporation is Minerva Neurosciences, Inc. The Certifi |
|
| June 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commissi |
|
| June 15, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 Minerva Neurosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36517 26-0784194 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q sel f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neuroscien |
|
| April 26, 2022 |
DEF 14A 1 d247036ddef14a.htm DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| April 26, 2022 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 14, 2022 |
Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 13, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commiss |
|
| April 13, 2022 |
Roluperidone Update Webcast: Wednesday, April 13, 2022, at 11:00 ET To participate, please dial (877) 312-5845 (domestic) or (765) 507-2618 (international) and refer to conference ID 2489714. |
|
| April 7, 2022 |
Exhibit 99.1 Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia Company to Host Webcast Wednesday, April 13, 2022 at 11am ET WALTHAM, Mass., April 7, 2022 ? (Globe Newswire) Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage |
|
| April 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commissi |
|
| March 14, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commissi |
|
| March 1, 2022 |
Exhibit 21.1 Subsidiaries of Minerva Neurosciences, Inc. Name Jurisdiction of Incorporation Mind-NRG Sarl Switzerland Minerva Neurosciences Securities Corporation Massachusetts |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36517 Minerva Neurosc |
|
| March 1, 2022 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.4 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 24, 2022, Minerva Neurosciences, Inc. (the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock. The following description of our common stock is a summa |
|
| February 28, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin Trial Results Confirm the Potential of Roluperidone To Treat Negative Symptoms and Improve Everyday Functioning in Patients with Schizophrenia WALTHAM, Mass. ? February 28, 2022 ? (Globe Newswire) Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage |
|
| February 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| February 14, 2022 |
NERV / Minerva Neurosciences Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8*) MINERVA NEUROSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 603380106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing o |
|
| February 11, 2022 |
NERV / Minerva Neurosciences Inc / Luthringer Remy - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Minerva Neurosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 603380106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 10, 2022 |
NERV / Minerva Neurosciences Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Minerva Neurosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 603380106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| January 18, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| January 5, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commis |
|
| January 5, 2022 |
Corporate Presentation January 2022 Exhibit 99.1 Forward-Looking Statement Safe-Harbor Forward-Looking Safe Harbor Statement This presentation contains forward-looking statements. Forward-looking statements are statements that are not historical facts, reflect management?s expectations as of the date of this presentation, and involve certain risks and uncertainties. Forward-looking statements incl |
|
| December 8, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2021 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| December 8, 2021 |
3 Authors: Michael Davidson1,2 MD, Jay Saoud1 PhD, Corinne Staner3 MD, Nadine Noel3 PhD, ?Sandra Werner3 PhD, Elisabeth Luthringer3 RN, Philip Harvey PhD, Gregory Strauss PhD, Mark Weiser4MD, Remy Luthringer1 PhD Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia Study registration: Eudra-CT: 2017-003333-29; NCT03397134 Affiliations: (1) Minerva Neurosciences; (2) Nicosia University Medical School; (3) PPRS, (4) University of Tel Aviv School of Medicine (6) University of Miami Miller School of Medicine (7) University of Georgia Minerva Neurosciences is the sponsor of the trials Exhibit 99. |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neuroscien |
|
| November 3, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission Waltham, Mass. ? November 3, 2021 ? (Globe Newswire) Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceut |
|
| November 3, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| October 12, 2021 |
Exhibit 10.1 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF GEOFF RACE This FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF GEOFF RACE (the ?Amendment?) is entered into this 11th day of October 2021 (the ?Effective Date?), by and between GEOFF RACE (the ?Employee?) and Mind-NRG SARL (the ?Company?). RECITALS A. The Company and the Employee have entered into that certain Employment Agreement effecti |
|
| October 12, 2021 |
Exhibit 99.1 Minerva Neurosciences Announces Promotion of Geoff Race to President Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA Waltham, Mass. ? October 11, 2021 ? (Globe Newswire) Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous |
|
| October 12, 2021 |
Exhibit 10.2 October 11th, 2021 Fred Ahlholm 48 Hawkins Lane North Andover, MA 01842 Re: Amended and Restated Employment Agreement Dear Fred, Minerva Neurosciences, Inc. (the ?Company?) is pleased to offer you continued employment on the terms set forth in this letter agreement (the ?Agreement?). 1. Employment. This Agreement replaces and supersedes the May 30, 2014 and the August 1, 2016 offer le |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2021 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| September 30, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Com |
|
| September 30, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration Waltham, Mass. ? September 30, 2021 ? (Globe Newswire) Minerva Neurosciences, Inc. (Nasdaq |
|
| September 8, 2021 |
Exhibit 10.1 September 2, 2021 Jay B. Saoud 271 Pepperell Road Groton, MA 01450 Re: Transition, Separation, and Consulting Agreement Dear Jay: This letter sets forth the terms of the transition, separation, and consulting agreement (the ?Agreement?) that Minerva Neurosciences, Inc. (the ?Company?) is offering to you to aid in your transition. 1. SEPARATION DATE. In connection with your decision to |
|
| September 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2021 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| September 8, 2021 |
Exhibit 99.1 Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES APPOINTMENT OF DR. RAMANA KUCHIBHATLA AS SENIOR VICE PRESIDENT AND HEAD OF RESEARCH & DEVELOPMENT Dr. Jay Saoud, Head of Research & Development, to retire from his current role and transition to an advisory role in which |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No.2) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 MINERVA NEUROSCIENCES, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 603 |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neurosciences, |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 MINERVA NEUROSCIENCES, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 60 |
|
| August 2, 2021 |
Exhibit (a)(1)(A) MINERVA NEUROSCIENCES, INC. 1601 TRAPELO ROAD, SUITE 286 WALTHAM, MA 02451 OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW RESTRICTED STOCK UNITS JULY 6, 2021 MINERVA NEUROSCIENCES, INC. SUMMARY TERM SHEET ? OVERVIEW OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW RESTRICTED STOCK UNITS This offer and withdrawal rights will expire at 5:00 p.m., Eastern Time, on Tuesday, August 3, 2021, unl |
|
| July 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 MINERVA NEUROSCIENCES, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 603380106 (CUSIP Numbe |
|
| July 6, 2021 |
Form of Reminder Email to Eligible Holders Regarding the Expiration of the Exchange Offer EX-99.A1G 8 d54260dex99a1g.htm EX-99.(A)(1)(G) Exhibit (a)(1)(G) FORM OF REMINDER EMAIL TO ELIGIBLE HOLDERS REGARDING THE EXPIRATION OF THE EXCHANGE OFFER From: Minerva Neurosciences, Inc. Re: REMINDER – Offer to Exchange Eligible Options for New Restricted Stock Units This email serves as a reminder that we are nearing the expiration of the Exchange Offer described in the Offer to Exchange Eligib |
|
| July 6, 2021 |
Notice of Withdrawal of Election Form EX-99.A1D 5 d54260dex99a1d.htm EX-99.(A)(1)(D) Exhibit (a)(1)(D) INSTRUCTIONS TO NOTICE OF WITHDRAWAL OF ELECTION FORM If you previously elected to accept the offer by Minerva Neurosciences, Inc. (“Minerva”) to exchange some or all of your outstanding Eligible Options for New Restricted Stock Units, subject to the terms and conditions of the Offer to Exchange Eligible Options for New Restricted St |
|
| July 6, 2021 |
Form of Email Confirming Receipt of Election Form EX-99.A1E 6 d54260dex99a1e.htm EX-99.(A)(1)(E) Exhibit (a)(1)(E) FORM OF EMAIL CONFIRMING RECEIPT OF ELECTION FORM From: Minerva Neurosciences, Inc. Re: Confirmation of Receipt of Election Form This message confirms that Minerva Neurosciences, Inc. (“Minerva”) has received your Election Form. This confirmation should not, however, be construed to imply that the Election Form you submitted has been |
|
| July 6, 2021 |
Form of Expiration Notice Email EX-99.A1J 11 d54260dex99a1j.htm EX-99.(A)(1)(J) Exhibit (a)(1)(J) FORM OF EXPIRATION NOTICE EMAIL From: Minerva Neurosciences, Inc. Re: Expiration of the Exchange Offer The Exchange Offer described in the Offer to Exchange Eligible Options for New Restricted Stock Units, dated July 6, 2021 (the “Offer Documents”), has expired, and no additional Election Forms or Notices of Withdrawal may be submit |
|
| July 6, 2021 |
Form of Announcement Email to Eligible Holders EX-99.A1B 3 d54260dex99a1b.htm EX-99.(A)(1)(B) Exhibit (a)(1)(B) FORM OF ANNOUNCEMENT EMAIL TO ELIGIBLE HOLDERS Subject: Minerva Neurosciences, Inc. Offer to Exchange Eligible Options for New Restricted Stock Units To: All Eligible Holders Date: July 6, 2021 We are pleased to announce that Minerva Neurosciences, Inc. (“Minerva,” “we,” “us” or “our”) is commencing an Offer to Exchange Eligible Opti |
|
| July 6, 2021 |
Exhibit (a)(1)(C) MINERVA NEUROSCIENCES, INC. 1601 TRAPELO ROAD, SUITE 286 WALTHAM, MA 0245 OPTION EXCHANGE – ELECTION FORM THIS OFFER AND YOUR WITHDRAWAL RIGHTS WILL EXPIRE AT 5:00 P.M., EASTERN TIME, ON TUESDAY, AUGUST 3, 2021, UNLESS EXTENDED Before completing and signing this Election Form, we encourage you to read the documents that make up this tender offer, including (1) the Offer to Exchan |
|
| July 6, 2021 |
Form of Email to Eligible Holders Confirming Acceptance of Eligible Options Exhibit (a)(1)(H) FORM OF EMAIL TO ELIGIBLE HOLDERS CONFIRMING ACCEPTANCE OF ELIGIBLE OPTIONS From: Minerva Neurosciences, Inc. |
|
| July 6, 2021 |
Offer to Exchange Eligible Options for New Restricted Stock Units, dated July 6, 2021 EX-99.A1A 2 d54260dex99a1a.htm EX-99.(A)(1)(A) Exhibit (a)(1)(A) MINERVA NEUROSCIENCES, INC. 1601 TRAPELO ROAD, SUITE 286 WALTHAM, MA 02451 OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW RESTRICTED STOCK UNITS JULY 6, 2021 MINERVA NEUROSCIENCES, INC. SUMMARY TERM SHEET — OVERVIEW OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW RESTRICTED STOCK UNITS This offer and withdrawal rights will expire at 5:00 p.m. |
|
| July 6, 2021 |
Form of Email Confirming Receipt of Notice of Withdrawal of Election Form EX-99.A1F 7 d54260dex99a1f.htm EX-99.(A)(1)(F) Exhibit (a)(1)(F) FORM OF EMAIL CONFIRMING RECEIPT OF NOTICE OF WITHDRAWAL OF ELECTION FORM From: Minerva Neurosciences, Inc. Re: Confirmation of Receipt of Notice of Withdrawal of Election Form This message confirms that Minerva Neurosciences, Inc. (“Minerva”) has received your Notice of Withdrawal of Election Form (“Notice of Withdrawal”). This conf |
|
| July 6, 2021 |
Form of Email Notice Regarding Rejection of Options for Exchange Exhibit (a)(1)(I) FORM OF EMAIL NOTICE REGARDING REJECTION OF OPTIONS FOR EXCHANGE From: Minerva Neurosciences, Inc. |
|
| June 16, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 Minerva Neurosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36517 26-0784194 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 12, 2021 |
Geoff Race Supplemental Retention Benefits Letter Agreement (redacted) EX-10.2 3 nerv-ex102184.htm EX-10.2 EXHIBIT 10.2 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.2Geoff Race Supplemental Retention Benefits Letter Agreement (redacted) April 27, 2021 Geoff Race [•••] Re:Supplemental Retention Benefit D |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neurosciences, |
|
| May 12, 2021 |
Remy Luthringer Supplemental Retention Benefits Letter Agreement (redacted) EX-10.1 2 nerv-ex101185.htm EX-10.1 EXHIBIT 10.1 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.1Remy Luthringer Supplemental Retention Benefits Letter Agreement (redacted) April 27, 2021 Remy Luthringer, PhD [•••] Re:Supplemental Rete |
|
| May 12, 2021 |
Form of Supplemental Retention Benefits Letter Agreement for Other Officers EXHIBIT 10.3 EXHIBIT 10.3Form of Executive Supplemental Retention Benefits Letter Agreement April 27, 2021 Re:Supplemental Retention Benefit Dear : You will recall that last year the Compensation Committee (the ?Committee?) of the Board of Directors (the ?Board?) of Minerva Neurosciences, Inc. (the ?Company?) adopted a retention program for certain of its key employees, pursuant to which the Compa |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2021 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commiss |
|
| March 8, 2021 |
EX-10.48 3 nerv-ex1048189.htm EX-10.48 Exhibit 10.48 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.48 Royalty Purchase Agreement (redacted) Execution Copy Royalty Purchase Agreement By and Between Minerva Neurosciences, Inc. and RPI 2 |
|
| March 8, 2021 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. EX-4.4 2 nerv-ex449.htm EX-4.4 Exhibit 4.4 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 4, 2021, Minerva Neurosciences, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following description of |
|
| March 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36517 Minerva Neurosc |
|
| March 8, 2021 |
EX-21.1 4 nerv-ex2117.htm EX-21.1 Exhibit 21.1 Subsidiaries of Minerva Neurosciences, Inc. Name Jurisdiction of Incorporation Mind-NRG Sarl Switzerland Minerva Neurosciences Securities Corporation Massachusetts |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Minerva Neurosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 603380106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 12, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7*) MINERVA NEUROSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 603380106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing o |
|
| February 10, 2021 |
SC 13G 1 tv01401-minervaneurosciences.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Minerva Neurosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 603380106 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule p |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Minerva Neurosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 603380106 Date of Event Which Requires Filing of this Statement: January 29, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| January 19, 2021 |
MINERVA NEUROSCIENCES AND ROYALTY PHARMA ANNOUNCE SALE OF SELTOREXANT ROYALTY FOR UP TO $155 MILLION EX-99.1 2 d945121dex991.htm EX-99.1 Exhibit 99.1 Contact: William B. Boni Minerva Neurosciences, Inc. (617) 600-7376 Royalty Pharma plc (212) 883-2295 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES AND ROYALTY PHARMA ANNOUNCE SALE OF SELTOREXANT ROYALTY FOR UP TO $155 MILLION Waltham, MA and New York, NY, January 19, 2021 – Minerva Neurosciences, Inc. (Nasdaq: NERV) and Royalty Pharma plc (Nasdaq: RP |
|
| January 19, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2021 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| December 1, 2020 |
Exhibit 99.1 Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone Waltham, MA, December 1, 2020 – Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the d |
|
| December 1, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| November 2, 2020 |
Michael Davidson Retention Benefits Letter Agreement (redacted EXHIBIT 10.7 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.7Michael Davidson Retention Benefits Letter Agreement (redacted) Michael Davidson [•••] Re:Retention Benefits Dear Michael: In recognition of the importance of your services t |
|
| November 2, 2020 |
Frederick Ahlholm Retention Benefits Letter Agreement (redacted) EXHIBIT 10.5 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.5Frederick Ahlholm Retention Benefits Letter Agreement (redacted) October 13, 2020 Frederick Ahlholm [•••] Re:Retention Benefits Dear Fred: In recognition of the importance of |
|
| November 2, 2020 |
Joseph Reilly Retention Benefits Letter Agreement (redacted) EX-10.6 7 nerv-ex106173.htm EX-10.6 EXHIBIT 10.6 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.6Joseph Reilly Retention Benefits Letter Agreement (redacted) October 13, 2020 Joseph Reilly [•••] Re:Retention Benefits Dear Joe: In recog |
|
| November 2, 2020 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neuroscien |
|
| November 2, 2020 |
Remy Luthringer Retention Benefits Letter Agreement (redacted) EXHIBIT 10.1 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.1Remy Luthringer Retention Benefits Letter Agreement (redacted) October 13, 2020 Remy Luthringer, PhD [•••] Re:Retention Benefits Dear Remy: In recognition of the importance o |
|
| November 2, 2020 |
Jay Saoud Retention Benefits Letter Agreement (redacted) EXHIBIT 10.3 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.3Jay Saoud Retention Benefits Letter Agreement (redacted) October 13, 2020 Jay B. Saoud [•••] Re:Retention Benefits Dear Jay: In recognition of the importance of your services |
|
| November 2, 2020 |
Geoff Race Retention Benefits Letter Agreement (redacted EXHIBIT 10.2 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.2Geoff Race Retention Benefits Letter Agreement (redacted) October 13, 2020 Geoff Race [•••] Re:Retention Benefits Dear Geoff: In recognition of the importance of your service |
|
| November 2, 2020 |
Devin Smith Retention Benefits Letter Agreement (redacted EXHIBIT 10.4 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.4Devin Smith Retention Benefits Letter Agreement (redacted) October 13, 2020 Devin Smith [•••] Re:Retention Benefits Dear Devin: In recognition of the importance of your servi |
|
| October 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commis |
|
| September 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| August 10, 2020 |
S-8 As filed with the Securities and Exchange Commission on August 7, 2020 Registration No. |
|
| August 3, 2020 |
EX-10.2 2 nerv-ex102120.htm EX-10.2 EXHIBIT 10.2 Certain information identified with brackets (“[***]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. CONFIDENTIAL SETTLEMENT AGREEMENT WHEREAS, Janssen Pharmaceutica, N.V. (“Janssen”) and Minerva Neurosciences, Inc. (“Minerva”) are parties (together, the “Partie |
|
| August 3, 2020 |
Amended and Restated 2013 Equity Incentive Plan EX-10.3 3 nerv-ex103210.htm EX-10.3 EXHIBIT 10.3 Minerva Neurosciences, Inc. Amended and Restated 2013 Equity Incentive Plan Adopted by Board of Directors on: December 19, 2013 Approved by the Stockholders on: December 19, 2013 Amended and Restated by the Board of Directors on: April 29, 2014 Amendment and Restatement Approved by the Stockholders on: June 2, 2014 Amended and restated by the Board |
|
| August 3, 2020 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neurosciences, |
|
| July 2, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| July 1, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| July 1, 2020 |
MINERVA NEUROSCIENCES EXERCISES RIGHT TO OPT OUT OF AGREEMENT WITH JANSSEN FOR SELTOREXANT (MIN-202) EX-99.1 2 d947910dex991.htm EX-99.1 Exhibit 99.1 Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES EXERCISES RIGHT TO OPT OUT OF AGREEMENT WITH JANSSEN FOR SELTOREXANT (MIN-202) • Preserves royalties payable to Minerva on worldwide sales of seltorexant • Eliminates all financial obligations w |
|
| June 25, 2020 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2020 Minerva Neurosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36517 (Commission File |
|
| June 5, 2020 |
EX-99.1 ROLUPERIDONE: Topline results from the Phase 3 trial: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-Controlled, Monotherapy, 12-Week Study to Evaluate the Efficacy and Safety of 2 Fixed Doses of MIN-101 in Adult Patients with Negative Symptoms of Schizophrenia, Followed by 40-Week Open-Label Extension June 5th, 2020 : NERV Exhibit 99.1 Forward-Looking Statement Safe-Harb |
|
| June 5, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| May 29, 2020 |
EX-99.1 Exhibit 99.1 Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES RESULTS FROM PHASE 3 TRIAL OF ROLUPERIDONE (MIN-101) FOR TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA • The 64 mg and 32 mg doses were not statistically significantly different from placebo at Week 12 on the p |
|
| May 29, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| May 4, 2020 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neurosciences, |
|
| April 28, 2020 |
DEF 14A 1 d860861ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Us |
|
| April 28, 2020 |
DEFA14A 1 d860861ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissi |
|
| April 1, 2020 |
EX-99.1 Roluperidone: A potential novel mechanism to treat the negative symptoms of schizophrenia William Carpenter MD John Kane MD Steven Marder MD Ofer Agid MD Remy Luthringer PhD Hosted by Minerva Neurosciences (Nasdaq: NERV) Tuesday, March 31, 2020 Exhibit 99.1 All trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. Forward-Look |
|
| April 1, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Com |
|
| March 13, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Com |
|
| March 13, 2020 |
MINERVA NEUROSCIENCES UPDATES MARKET ON SHARE PRICE DROP AND TRADING HALT EX-99.1 Exhibit 99.1 MINERVA NEUROSCIENCES UPDATES MARKET ON SHARE PRICE DROP AND TRADING HALT WALTHAM, Mass., March 12, 2020 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central nervous system (CNS) disorders, wishes to address a sharp reduction of its sh |
|
| March 9, 2020 |
EX-99.1 Exhibit 99.1 Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES REPORTS FISCAL 2019 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS AND BUSINESS UPDATES Company confirms timing of expected top-line results from Phase 3 roluperidone trial in Q2 2020 Management to host conference call toda |
|
| March 9, 2020 |
NERV / Minerva Neurosciences, Inc. 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36517 Minerva Neurosc |
|
| March 9, 2020 |
Exhibit 21.1 Subsidiaries of Minerva Neurosciences, Inc. Name Jurisdiction of Incorporation Mind-NRG Sarl Switzerland Minerva Neurosciences Securities Corporation Massachusetts |
|
| March 9, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| March 9, 2020 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. Exhibit 4.4 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 5, 2020, Minerva Neurosciences, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following description of our common stock is a summary, |
|
| February 14, 2020 |
NERV / Minerva Neurosciences, Inc. / FEDERATED INVESTORS INC /PA/ Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6*) MINERVA NEUROSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 603380106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing o |
|
| February 12, 2020 |
NERV / Minerva Neurosciences, Inc. / Luthringer Remy - AMENDED SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Minerva Neurosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 603380106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 5, 2020 |
EX-99.1 Exhibit 99.1 Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 3 TRIAL OF ROLUPERIDONE FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA Data readout expected in the second quarter of 2020 Waltham, MA, February 5, 2020 – Minerv |
|
| February 5, 2020 |
Financial Statements and Exhibits, Other Events 8-K 1 d884459d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction |
|
| January 6, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Co |
|
| January 6, 2020 |
EX-99.1 Exhibit 99.1 Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES COMPLETION OF PATIENT SCREENING IN PHASE 3 TRIAL OF ROLUPERIDONE FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA Top-line results expected in the second quarter of 2020 Waltham, MA, January 6, 2020 – Mine |
|
| December 18, 2019 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2019 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) ( |
|
| December 18, 2019 |
EX-99.1 Exhibit 99.1 Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES REPORTS TOPLINE RESULTS FROM PHASE 2B TRIAL OF MIN-117 IN MAJOR DEPRESSIVE DISORDER • MIN-117 study did not meet its primary (MADRS) and key secondary (HAM-A) endpoints • MIN-117 was generally well-tolerated with a safety |
|
| December 10, 2019 |
NERV / Minerva Neurosciences, Inc. / FEDERATED INVESTORS INC /PA/ Passive Investment SC 13G/A 1 minervaform.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5*) MINERVA NEUROSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 603380106 (CUSIP Number) November 30, 2019 (Date of Ev |
|
| November 4, 2019 |
NERV / Minerva Neurosciences, Inc. 10-Q - Quarterly Report - 10-Q yahf UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neurosc |
|
| November 4, 2019 |
Commercial Supply Agreement with Catalent Germany Schorndorf GmbH, dated as of September 18, 2019 EX-10.1 2 nerv-ex10158.htm EX-10.1 Certain information identified with brackets (“[***]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXECUTION VERSION EXHIBIT 10.1 COMMERCIAL SUPPLY AGREEMENT MIN-101 Tablets THIS COMMERCIAL SUPPLY AGREEMENT (“Agreement”) is made as of this 2 day of September, 2019 (“Effecti |
|
| November 4, 2019 |
Amended and Restated Bylaws of the Registrant EXHIBIT 3.2 AMENDED AND RESTATED BYLAWS OF MINERVA NEUROSCIENCES, INC. (a Delaware Corporation) Adopted as of November 1, 2019 ARTICLE I OFFICES AND FISCAL YEAR SECTION 1.01. Registered Office. The registered office of the corporation shall be Corporation Service Company, 2711 Centerville Road, Suite 400, City of Wilmington, County of New Castle, State of Delaware until otherwise established by re |
|
| October 1, 2019 |
Financial Statements and Exhibits, Other Events 8-K 1 d813246d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2019 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction |
|
| October 1, 2019 |
EX-99.1 Exhibit 99.1 Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES UPDATE FOR THREE CLINICAL TRIALS Company to host conference call at 8:30 a.m. today (dial-in information below) Waltham, MA, October 1, 2019 – Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharm |
|
| September 24, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2019 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) |
|
| September 24, 2019 |
EX-99.1 Exhibit 99.1 Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone WALTHAM, Mass. and SOMERSET, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, and Catalent, the |
|
| August 5, 2019 |
NERV / Minerva Neurosciences, Inc. 10-Q - Quarterly Report - 10-Q 10-Q 1 nerv-10q20190630.htm 10-Q yahf UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File N |
|
| June 26, 2019 |
EX-99.1 2 d767481dex991.htm EX-99.1 Exhibit 99.1 Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia June 24, 2019 • Primary endpoint, defined as Latency to Persistent Sleep (LPS) at Night 1, showed improvement with a p-value £0.001 after treatment with 10 and 20 mg doses of seltorexant • Key secondary |
|
| June 26, 2019 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2019 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| June 18, 2019 |
NERV / Minerva Neurosciences, Inc. / Index Venture Associates III Ltd - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) MINERVA NEUROSCIENCES, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 603380106 (CUSIP Number) 44 Esplanade, 5th Floor, St. Helier, Jersey JE1 3FG, Channel Islands and 44 Esplanade, St. Helier, Je |
|
| May 31, 2019 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2019 Minerva Neurosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36517 26-0784194 (State or Other Jurisdiction of Incorporation) (Commi |
|
| May 16, 2019 |
Financial Statements and Exhibits, Other Events 8-K 1 d750055d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2019 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of |
|
| May 16, 2019 |
EX-99.1 Exhibit 99.1 Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs May 13, 2019 • Potential first-in-class, oral specific orexin-2 inhibitor demonstrates statistically significant improvement in MADRS scores at 6 weeks compared to placebo • Well tolera |
|
| May 6, 2019 |
NERV / Minerva Neurosciences, Inc. 10-Q Quarterly Report 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neurosciences, |
|
| May 6, 2019 |
Employment Agreement between Devin Smith and the Registrant, dated as of June 12, 2018 EX-10.1 2 nerv-ex101122.htm EX-10.1 EXHIBIT 10.1 June 12, 2018 Dear Devin, This agreement (hereafter "Employment Agreement") will formalize the terms and conditions of your employment with Minerva Neurosciences, Inc. (the "Company"). 1.Employment. You will commence employment with the Company on July 19, 2018, (the “Start Date”) and the terms of your employment are set forth in this agreement date |
|
| April 17, 2019 |
NERV / Minerva Neurosciences, Inc. DEFA14A DEFA14A 1 d677139ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissi |
|
| April 17, 2019 |
NERV / Minerva Neurosciences, Inc. DEF 14A DEF 14A 1 d677139ddef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissio |
|
| April 11, 2019 |
NERV / Minerva Neurosciences, Inc. RW RW April 11, 2019 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| March 12, 2019 |
Exhibit 21.1 Subsidiaries of Minerva Neurosciences, Inc. Name Jurisdiction of Incorporation Mind-NRG Sarl Switzerland Minerva Neurosciences Securities Corporation Massachusetts |
|
| March 12, 2019 |
NERV / Minerva Neurosciences, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36517 Minerva Neurosc |
|
| February 14, 2019 |
NERV / Minerva Neurosciences, Inc. / Luthringer Remy - SC 13G Passive Investment SC 13G 1 d632189dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Minerva Neurosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 603380106 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 13, 2019 |
NERV / Minerva Neurosciences, Inc. / FEDERATED INVESTORS INC /PA/ Passive Investment SC 13G/A 1 form.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4*) MINERVA NEUROSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 603380106 (CUSIP Number) December 31, 2018 (Date of Event Whi |
|
| November 5, 2018 |
NERV / Minerva Neurosciences, Inc. 10-Q (Quarterly Report) yahf UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neurosc |
|
| October 5, 2018 |
SC 13D/A: Amendment No. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) MINERVA NEUROSCIENCES, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 603380106 (CUSIP Number) No. 1 Seaton Place, St. Helier, Jersey JE4 8YJ, Channel Islands and 44 Esplanade, St |
|
| August 22, 2018 |
NERV / Minerva Neurosciences, Inc. CORRESP CORRESP August 22, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| August 10, 2018 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate EX-4.9 EXHIBIT 4.9 MINERVA NEUROSCIENCES, INC. and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF [ ], 20 MINERVA NEUROSCIENCES, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between MINERVA NEUROSCIENCES, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] or |
|
| August 10, 2018 |
NERV / Minerva Neurosciences, Inc. FORM S-3 S-3 1 d602457ds3.htm FORM S-3 Table of Contents As filed with the Securities and Exchange Commission on August 10, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 26-0784194 (State or other ju |
|
| August 10, 2018 |
EX-4.6 3 d602457dex46.htm EX-4.6 EXHIBIT 4.6 MINERVA NEUROSCIENCES, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Secur |
|
| August 10, 2018 |
Statement Regarding Computation of Ratios EX-12.1 Exhibit 12.1 STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (in thousands) • The following table sets forth our ratio of earnings to fixed charges and our ratio of earnings to combined fixed charges and preferred stock dividends for the years ended December 31, 2013, 2014, 2015, 2016, 2017 and for the six months ended June 30, 2018. As the ratios of earnings to fixed |
|
| August 10, 2018 |
Form of Common Stock Warrant Agreement and Warrant Certificate EX-4.8 EXHIBIT 4.8 MINERVA NEUROSCIENCES, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF [ ], 20 MINERVA NEUROSCIENCES, INC. FORM OF COMMON STOCK WARRANT AGREEMENT COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between MINERVA NEUROSCIENCES, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized a |
|
| August 10, 2018 |
Form of Debt Securities Warrant Agreement and Warrant Certificate EX-4.10 EXHIBIT 4.10 MINERVA NEUROSCIENCES, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [ ], 20 MINERVA NEUROSCIENCES, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between MINERVA NEUROSCIENCES, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] |
|
| August 10, 2018 |
EX-1.2 Exhibit 1.2 EXECUTION VERSION OPEN MARKET SALE AGREEMENTSM August 10, 2018 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Minerva Neurosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), sh |
|
| August 2, 2018 |
Amended and Restated Non-Employee Director Compensation Plan EXHIBIT 10.2 AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PLAN Approved: March 7, 2018 Effective: April 1, 2018 Effective as of April 1, 2018, each non-employee member of the board of directors (the “Board”) of Minerva Neurosciences, Inc. (the “Company”) will receive an annual cash retainer of $35,000, the Lead Independent Director will receive an additional cash retainer of $10,000, an |
|
| August 2, 2018 |
NERV / Minerva Neurosciences, Inc. 10-Q (Quarterly Report) yahf UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neuroscience |
|
| July 17, 2018 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2018 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) |
|
| July 17, 2018 |
MINERVA NEUROSCIENCES ELECTS JERYL HILLEMAN TO BOARD OF DIRECTORS EX-99.1 Exhibit 99.1 Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ELECTS JERYL HILLEMAN TO BOARD OF DIRECTORS Waltham, MA, July 17, 2018 – Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervo |
|
| June 15, 2018 |
S-8 As filed with the Securities and Exchange Commission on June 15, 2018 Registration No. |
|
| June 11, 2018 |
EX-99.1 Exhibit 99.1 MINERVA NEUROSCIENCES, INC. AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN (Amended and Restated as of April 21, 2018) ARTICLE 1 GENERAL PROVISIONS 1.1 PURPOSE OF THE PLAN This Amended and Restated 2013 Equity Incentive Plan (the “Plan”) is intended to promote the interests of Minerva Neurosciences, Inc., a Delaware corporation, by providing eligible persons in the Corporatio |
|
| June 11, 2018 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2018 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) ( |
|
| May 3, 2018 |
NERV / Minerva Neurosciences, Inc. 10-Q (Quarterly Report) 10-Q 1 nerv-10q20180331.htm 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| April 24, 2018 |
NERV / Minerva Neurosciences, Inc. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 24, 2018 |
NERV / Minerva Neurosciences, Inc. DEF 14A DEF 14A 1 d515561ddef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissio |
|
| March 22, 2018 |
EX-99.1 March 2018 2018: MILESTONES ON THE HORIZON Exhibit 99.1 All trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. Forward-Looking Statement Safe-Harbor This presentation contains forward-looking statements about Minerva Neurosciences which are subject to the safe harbor provisions of the Private Securities Litigation Reform Ac |
|
| March 22, 2018 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2018 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Com |
|
| March 12, 2018 |
S-8 1 d509396ds8.htm S-8 As filed with the Securities and Exchange Commission on March 12, 2018 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 26-0784194 (State or other jurisdiction of incorporation or organiz |
|
| March 12, 2018 |
Exhibit 21.1 Subsidiaries of Minerva Neurosciences, Inc. Name Jurisdiction of Incorporation Mind-NRG Sarl Switzerland Minerva Neurosciences Securities Corporation Massachusetts |
|
| March 12, 2018 |
NERV / Minerva Neurosciences, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36517 Minerva Neurosc |
|
| February 21, 2018 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2018 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) ( |
|
| February 21, 2018 |
EX-99.1 February 2018 2018: MILESTONES ON THE HORIZON Exhibit 99.1 All trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. Forward-Looking Statement Safe-Harbor This presentation contains forward-looking statements about Minerva Neurosciences which are subject to the safe harbor provisions of the Private Securities Litigation Reform |
|
| February 14, 2018 |
NERV / Minerva Neurosciences, Inc. / FEDERATED INVESTORS INC /PA/ Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3*) MINERVA NEUROSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 603380106 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing o |
|
| February 14, 2018 |
NERV / Minerva Neurosciences, Inc. / Cormorant Asset Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Minerva Neurosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 603380106 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 14, 2018 |
SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A (Rule 13d-102) (Amendment No. |
